VGXI Inc, a Texas-based contract developer and manufacturer (CDMO) specialising in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines and RNA medicines, announced on Wednesday the appointment of Stephanie Burke as chief accounting officer (CAO).
Burke has more than a decade of accounting and leadership expertise. She has served in leadership roles managing both the VGXI Accounting/Finance and Materials teams.
Previously, Burke was financial controller at Manuli RYCO / Fliuconnecto and general manager of International Expo Service.
VGXI's CEO, Young Park, said: "Stephanie has been an invaluable member of the VGXI team since 2015. Her exceptional financial acumen coupled with her leadership skills make her the ideal candidate for the chief accounting officer position.
"This well-deserved promotion recognises the significant contributions Stephanie has made to VGXI during her tenure and she will undoubtedly play a critical role in shaping our financial strategies as we enter our next phase."
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Bavarian Nordic secures additional USD156.8m US government contract
myTomorrows names new director
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
Latigo Biotherapeutics names new chief executive officer
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine